The Sioux Community Cancer Consortium (SCCC) is a two component, one affiliate, community based clinical cancer research organization. The SCCC was founded in 1983 and has been a continuing clinical community oncology program of the National Cancer Institute (NCI) since that time. The two major components of the SCCC are in Sioux Falls, South Dakota and Sioux City, Iowa. The Sioux Falls, South Dakota component has an affiliate at Fort Collins, Colorado. The two component sites are separated by a mere ninety miles on Interstate 29 in the rural Midwest. The SCCC is the major source of clinical cancer research sponsored by the NCI in Sioux Falls, South Dakota and the only immediately available source of clinical cancer research sponsored by the NCI in Sioux City, Iowa and Fort Collins, Colorado. The geographic catchment area for the SCCC covers approximately 105,000 square miles in the southeastern South Dakota, southwestern Minnesota, northwestern Iowa, and northeastern Nebraska. The Fort Collins affiliate covers an approximate radius of 35,000 square miles. The primary research base for the SCCC will remain the North Central Cancer Treatment Group (NCCTG) with affiliate status with the Eastern Cooperative Oncology Group (ECOG) through the NCCTG and affiliate status with the Children's Cancer Study Group (CCSG) through the Mayo Clinic membership in the CCSG. Specialty group affiliation with the National Surgical Adjuvant Breast and Bowel Project (NSABP) will continue along with proposed involvement in the Breast Cancer Prevention Trial II. The continued specific objective of this application is to continue to make available clinical cancer treatment and cancer control research protocols in our area. One of the goals of the SCCC is to achieve in the region of 150 credits for clinical cancer treatment protocols and 100 credits for cancer control research protocols per year. The SCCC consists of 22 core investigators in medical oncology, radiation oncology, and pediatric oncology. There are a number of supporting physicians and/or investigators in the surgery, pathology, and medical practice arena. This is a realistic goal based on the past accomplishments of the SCCC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035103-17
Application #
6171978
Study Section
Special Emphasis Panel (ZCA1-SRRB-7 (J4))
Project Start
1987-08-30
Project End
2004-05-31
Budget Start
2000-06-01
Budget End
2001-05-31
Support Year
17
Fiscal Year
2000
Total Cost
$376,089
Indirect Cost
Name
Sanford Research/Usd
Department
Type
DUNS #
City
Sioux Falls
State
SD
Country
United States
Zip Code
57104
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Bhatia, Aarti K; Lee, Ju-Whei; Pinto, Harlan A et al. (2017) Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer 123:4653-4662
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Schild, Steven E; Hillman, Shauna L; Tan, Angelina D et al. (2017) Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol 12:697-703
Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671
Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ? 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Schneider, Bryan P; O'Neill, Anne; Shen, Fei et al. (2015) Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). Br J Cancer 113:1651-7
Liu, Heshan; Tan, Angelina D; Qin, Rui et al. (2015) Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients. SOJ Anesthesiol Pain Manag 2:
Wagner-Johnston, Nina D; Sloan, Jeff A; Liu, Heshan et al. (2015) 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial. Cancer 121:2537-43

Showing the most recent 10 out of 72 publications